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Novelty and impact: 
Medications that decrease lower oesophageal sphincter pressure (benzodiazepines, 
calcium channel blockers, nitrates, xanthines and β2 agonists) increase acid reflux, an 
oesophageal adenocarcinoma risk factor.  Previous studies of associations between 
these medications and cancer risk have reached inconsistent conclusions, potentially 
reflecting limited power. We conducted the largest study yet using two independent 
datasets.  Medications that decrease sphincter pressure were not associated with 
increased oesophageal cancer, apart from β2 agonists. The β2 agonist association 
merits further investigation. 
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ABSTRACT 
 
Excessive lower oesophageal sphincter relaxation increases gastro-oesophageal acid 
reflux, an oesophageal adenocarcinoma risk factor. Medications that relax this 
sphincter (benzodiazepines, calcium channel blockers, nitrates, β2 agonists and 
xanthines) could promote cancer. These medications were investigated in two 
independent datasets. In the Scottish Primary Care Clinical Informatics Unit (PCCIU) 
database, a nested case-control study of oesophageal cancer was performed using GP 
prescription records. Conditional logistic regression was used to calculate odds ratios 
(OR) and 95% confidence intervals (CIs) for medication use and oesophageal cancer. 
In UK Biobank, a cohort study was conducted using self-reported medication use. 
Cox regression was used to calculate hazard ratios (HRs) and 95% CIs for medication 
use and oesophageal cancer, and by tumour subtype. Overall, 1,979 oesophageal 
cancer patients were matched to 9,543 controls in PCCIU, and 355 of 475,768 
participants developed oesophageal cancer in UK Biobank. None of the medications 
investigated were significantly associated with oesophageal cancer risk apart from β2 
agonists, which were associated with increased oesophageal cancer risk in PCCIU 
(adjusted OR 1.38, 95% CI 1.12, 1.70) but not in UK Biobank (adjusted HR 1.21, 
95% CI 0.70, 2.08). Medications that relax the lower oesophageal sphincter were not 
associated with oesophageal cancer, apart from β2 agonists. This increased cancer risk 
in β2 agonist users merits further investigation.  
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INTRODUCTION 
 
Oesophageal cancer is the eighth most common cancer worldwide, accounting for 
400,000 deaths each year.1 Over recent decades survival from oesophageal cancer has 
remained poor (12% 5-year survival rate in Europe).2  
 
Prolonged relaxation of the lower oesophageal sphincter results in increased gastro-
oesophageal reflux,3 a known risk factor for oesophageal adenocarcinoma.4 Although 
the relationship between lower oesophageal sphincter tone and squamous cell 
carcinoma is less clearly established, non-acid gastro-oesophageal reflux has been 
associated with this cancer subtype.5,6 Through smooth muscle relaxation 
mechanisms, several commonly used medications have been shown to relax the lower 
oesophageal sphincter, including benzodiazepines, calcium channel blockers, nitrates, 
β2 agonists and xanthines,7–12 with the greatest reduction in pressure being caused by 
β2 agonists (30%).10 Millions of these medications are prescribed each year for 
conditions such as anxiety, hypertension, angina and asthma, respectively.13,14  
 
However, few epidemiological studies have explored the relationship between these 
medications and oesophageal cancer. Where studied, statistical power has been 
limited, as shown in a recent meta-analysis of these medications and oesophageal 
cancer risk, which included benzodiazepines (total of 406 cases), calcium channel 
blockers (total of 875 cases), nitrates (total of 980 cases), β2 agonists (total of 1,291 
cases) and xanthines (total of 984 cases).15–19 Additionally, three of these studies 
relied upon self-reported medication use, and are therefore prone to recall bias.16,17,19 
Furthermore, these studies have observed inconsistent results for some medications, 
Page 4 of 34International Journal of Cancer
 5
for example xanthines (specifically, theophylline).17–19 Given the widespread use of 
these medications it is a priority to establish if they increase oesophageal cancer risk. 
 
We conducted two large independent population-based studies from Scotland and 
England to explore the association between medications that reduce lower 
oesophageal sphincter tone and the risk of developing oesophageal cancer.
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METHODS 
 
PCCIU: Data source 
The Primary Care Clinical Informatics Unit Research (PCCIU) database contains 
computerised GP records including clinical diagnoses and prescriptions for 
approximately 15% of Scotland.20 The PCCIU contains over two million patients 
registered at 393 Scottish GPs. Access to the PCCIU data was approved by the 
Research Applications and Data Management Team, University of Aberdeen. Ethical 
approval for the PCCIU analysis was obtained from the School of Medicine, Dentistry 
and Biomedical Sciences Research Ethics Committee at Queen’s University Belfast 
(reference number: 15.43).  
 
PCCIU: Study design 
A nested case-control study was conducted with cases defined as patients with a first 
ever diagnosis of oesophageal cancer (Read code category: B10) between January 
1999 and April 2011. Up to five controls were randomly selected for each case 
matched on age, gender, year of diagnosis and general practice (GP). The index date 
for the cases was defined as the date of diagnosis of oesophageal cancer. The index 
date for the controls was the diagnosis date of their matched case. The start of the 
exposure period was the latest of 1st January 1996 (as prescriptions prior to this were 
less likely to have been electronically recorded) or the date of patient registration at a 
GP practice. Additionally, the start of the exposure period was truncated to the latest 
start date within each matched set of a case and controls to ensure all members of the 
matched set had an identical length of exposure period, removing the risk of time-
window bias.21 Cases and controls with a previous cancer diagnosis (other than non-
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melanoma skin cancer), and those with less than three years of prescription records 
prior to index date, were excluded. The end of the exposure period was one year prior 
to the index date to avoid reverse causation due to increased exposure to healthcare 
professionals following symptoms of cancer.   
 
PCCIU: Exposure data 
The medication groups of interest were those that relax the lower oesophageal 
sphincter: benzodiazepines, calcium channel blockers, nitrates, β2 agonists and 
xanthines. Supplementary Table 1 contains a list of medications included which were 
identified from the British National Formulary (71st edition).13 Medication use was 
determined from GP prescription records).  
 
PCCIU: Confounders 
Confounders were identified from GP records in the exposure period defined above. 
Based on the Charlson index,22 twelve comorbidities were identified using GP 
diagnosis codes (including acute myocardial infarction, congestive cardiac failure, 
peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive 
pulmonary disease [COPD], connective tissue disease, peptic ulcer disease, diabetes 
mellitus, rheumatoid arthritis, chronic kidney disease and liver disease). Lifestyle risk 
factors for oesophageal cancer including smoking (never smoker, ex-smoker or 
current smoker), alcohol consumption (none, low [e.g., moderate or light drinker], or 
high intake [e.g., above recommended limits, chronic alcoholism]) and obesity (obese 
[BMI>30] or not obese) were extracted from GP records. Postcode of the GP practice 
was used to assign deprivation fifths using the Scottish Index of Multiple 
Deprivation.23 Aspirin and statin use within the exposure period was identified, as 
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inverse associations have been shown with oesophageal cancer.24,25  
 
PCCIU: Statistical analysis 
We calculated descriptive statistics, comparing the demographics and clinical 
characteristics of cases and controls. Conditional logistic regression was used to 
calculate odds ratios (OR) and 95% confidence intervals (95% CI) for the association 
between medication use (in the exposure period) and risk of oesophageal cancer. In 
the main analysis, the matched design accounted for age, gender, general practice and 
year of diagnosis, with additional adjustments made for comorbidities (as described), 
and aspirin and statin use. As the patients were matched on general practice, they 
were inherently matched on deprivation level, as the available deprivation measure 
was based upon the address of their GP practice. In the main analysis for respiratory-
based medications studied (β2 agonists and xanthines) additional adjustment for 
steroid-based inhaler medication were conducted, but a sensitivity analysis was also 
added not adjusting for these medications to avoid the potential for over-adjustment. 
Analyses were repeated by number of prescriptions and by medication (restricted to 
medications prescribed to at least 1% of the patients in the analysis) (Supplementary 
Table 1). 
 
A sensitivity analysis was conducted additionally adjusting for lifestyle factors 
(smoking, alcohol and obesity) using both a complete case approach and multiple 
imputation. The imputation used ordered logit models with age, gender and 
deprivation, separately for cases and controls. Multiple imputation with chained 
equations is a simulation-based approach for handling missing data which can lead to 
valid statistical inferences.26 Sensitivity analyses were also conducted investigating 
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the impact of excluding prescriptions in the two years prior to the index date and 
defining medication users as patients with at least three prescriptions. Finally, we 
repeated the analysis combining gastric cancer (based upon Read code category B11) 
and oesophageal cancers as GPs could have misclassified junctional oesophageal 
carcinomas as gastric cancer.27  
 
UK Biobank: Data source 
The UK Biobank contains approximately 500,000 individuals aged between 40 and 
69 from England, Scotland and Wales recruited between 2006 and 2010. The UK 
Biobank is linked to cancer registry data from the Health and Social Care Information 
Centre (in England and Wales) and the Scottish Cancer Registry (in Scotland).28 
The UK Biobank was approved by the North West Multi-Centre Research Ethics 
Committee, and all participants provided written informed consent.  
 
UK Biobank: Study design 
A prospective cohort study was conducted. Cases of oesophageal cancer were 
identified from cancer-registry records (ICD code C15) up to 2014. Patients with a 
previous cancer diagnosis, apart from non-melanoma skin cancer, were excluded.  
Patients were followed from 1 year after baseline (removing cancers that may have 
been present at baseline) until the date of cancer or censoring on the earlier of death, 
emigration or 30th June 2014 (the date at which cancer registry data was complete).  
 
UK Biobank: Exposure data 
Self-reported use of medications outlined previously was determined at the baseline 
electronic touchscreen data entry system or interview.  
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UK Biobank: Confounders 
All confounders were determined from the baseline visit. The twelve comorbidities 
previously mentioned were identified from patient interview/touch screen at baseline. 
In addition, other recognised risk factors retrieved from the UK Biobank database 
were hypertension, Alzheimer’s disease, fruit and vegetable intake and educational 
degree. Lifestyle risk factors including smoking (never, former or current) and alcohol 
consumption (none, moderate [≤14 units per week], heavy [>14 units per week]) were 
determined from the electronic touchscreen data entry system, at baseline. BMI was 
calculated from height and weight measurements recorded at baseline by trained 
research staff, and categorised (underweight [<18.5], normal weight [18.5-24.99], 
overweight [25-29.99], obese [>30]). The Townsend score based upon postcode of 
residence was determined as a measure of deprivation.29 Self-reported aspirin and 
statin use were also identified. 
 
UK Biobank: Statistical analysis 
The UK Biobank cohort was analysed using Cox regression with age as the 
underlying time scale (individuals were considered at risk from birth and under 
observation from age at baseline, left truncated) to calculate hazard ratios (HR) and 
95% CIs for the association between medication use and oesophageal cancer. An 
initial adjusted analysis was conducted including gender, comorbidities, deprivation 
level, statin and aspirin use, for comparison with PCCIU estimates (not shown). The 
UK Biobank analysis contained further adjustment of other factors known to increase 
cancer risk which were not available in the PCCIU dataset, including lifestyle factors 
(including smoking, alcohol consumption and obesity), hypertension, Alzheimer’s 
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disease, fruit and vegetable intake and educational degree. These adjustments made 
little difference to the estimates and only these estimates are shown. Similar to the 
PCCIU analysis, additional adjustment for steroid-based inhaler medication was 
included for patients using respiratory-based medications (β2 agonists and xanthines). 
Sensitivity analysis was conducted by histological subtype (adenocarcinoma or 
squamous cell carcinoma). A sensitivity analysis was conducted starting follow-up at 
2 years after diagnosis. Sensitivity analyses were conducted for β2 agonists stratifying 
by asthma in order to reduce the risk of confounding by indication, and after 
adjustment for asthma. Finally, for comparison with β2 agonist association, a separate 
analysis of inhaled steroid medication was conducted (as these are used to treat 
asthma and COPD, but are not known to relax the lower oesophageal sphincter). 
Analysis was performed using STATA 14 (StataCorp LP, College Station, TX, USA).
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RESULTS 
 
PCCIU 
In PCCIU there were 1,979 oesophageal cancer cases and 9,543 control patients 
(Table 1). The median exposure time was 5.5 years (range 3.0-15.1 years). 
Oesophageal cancer cases were more likely to smoke, have higher alcohol intake and 
be diagnosed with COPD and peptic ulcer disease.  
 
Overall, a greater proportion of oesophageal cancer cases compared with controls 
used lower oesophageal sphincter relaxing medications (45.2% versus 39.1%). After 
adjustment for confounding, these medications were associated with a 23% increase 
in oesophageal cancer risk (adjusted OR 1.23 95% CI 1.10, 1.38) (Table 2). This 
association did not follow an exposure response as the adjusted OR for 1 to 12 
prescriptions was 1.30 (95% CI 1.13, 1.48), whilst the adjusted OR for >12 
prescriptions was 1.17 (95% CI 1.02, 1.35).  
 
This association was largely driven by β2 agonists, which were associated with a 38% 
increase in oesophageal cancer risk (adjusted OR 1.38, 95% CI 1.12, 1.70). The 
adjusted OR for 1 to 12 prescriptions was 1.42 (95% CI 1.14, 1.77) but the adjusted 
OR for greater use was 1.26 (95% CI 0.94, 1.69). Further analysis of specific 
respiratory-based medications showed only those containing salbutamol were 
significantly associated with oesophageal cancer (adjusted OR 1.26, 95% CI 1.03, 
1.54) (Supplementary Table 2). There was little evidence of an association between 
oesophageal cancer risk and the other medications that reduce lower oesophageal 
sphincter pressure, specifically benzodiazepines (adjusted OR 0.94, 95% CI 0.79, 
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1.11), calcium channel blockers (adjusted OR 1.05, 95% CI 0.92, 1.20), nitrates 
(adjusted OR 1.09, 95% CI 0.92, 1.29) and xanthines (adjusted OR 1.40, 95% CI 
0.88, 2.22) (Table 2).  
 
In sensitivity analyses, the associations were generally similar when the 2 years prior 
to diagnosis were removed, when a minimum of 3 prescriptions were investigated and 
when adjustments for lifestyle factors were included, using either complete case or 
multiple imputation (Table 3). Analysis excluding the additional adjustment for 
steroid-based inhaler medication conducted for respiratory-based medications (β2 
agonists and xanthines) had minimal effect on results, with β2 agonist medication 
remaining statistically significantly associated with oesophageal cancer (adjusted HR 
1.27, 95% CI 1.08, 1.48). Associations were also similar for combined gastric or 
oesophageal cancer (Supplementary Table 3).  
 
UK Biobank  
The UK Biobank cohort contained 475,768 participants of which 355 were diagnosed 
with oesophageal cancer (Table 1). The median follow-up time was 5.6 years (range 
1.0-8.6 years). In UK Biobank those with oesophageal cancer were more likely to be 
male, older, smoke, have higher alcohol intake, have higher BMI, and have COPD, 
amongst other comorbidities. 
 
Overall, in comparison to those without oesophageal cancer a greater proportion of 
people who developed oesophageal cancer used one or more lower oesophageal 
sphincter relaxing medication (23.1% versus 14.1%). After adjustment for 
confounders, there was no evidence of an association between use of one or more 
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medication which lower oesophageal sphincter pressure and oesophageal cancer 
(adjusted HR 1.29, 95% CI 0.97, 1.71) (Table 4). Further, there was also no evidence 
of association for specific medication classes and oesophageal cancer: 
benzodiazepines (adjusted HR 1.47, 95% CI 0.54, 3.96), calcium channel blockers 
(adjusted HR 0.94, 95% CI 0.64, 1.36), nitrates (adjusted HR 0.85, 95% CI 0.40, 
1.82), β2 agonists (adjusted HR 1.21, 95% CI 0.70, 2.08) and xanthines (adjusted HR 
2.46, 95% CI 0.58, 10.32) (Table 4).  
 
Analyses by histological subtype also showed medications that relax the lower 
oesophageal sphincter are not associated with risk of oesophageal adenocarcinoma or 
squamous cell carcinoma. Further analyses demonstrated that there was no association 
between β2 agonist use and oesophageal cancer in patients with or without asthma 
(adjusted HR 1.69, 95% CI 0.76, 3.78 and adjusted HR 0.57, 95% CI 0.17, 1.92, 
respectively) (Table 5). Similarly, after additional adjustment for asthma, there was 
no evidence of β2 agonist association with oesophageal cancer (adjusted HR 1.24, 
95% CI 0.66, 2.34). However, there was an association between β2 agonist use and 
oesophageal cancer when adjustment for steroid-based inhalers was removed 
(adjusted HR 1.66, 95% CI 1.16, 2.37) (Table 5).  
 
Users of steroid based inhalers, prescribed for asthma, had a significantly increased 
risk of oesophageal cancer (adjusted HR 1.94, 95% CI 1.32, 2.86). Analyses by drug 
type revealed in the UK Biobank no specific individual mediation was associated with 
increased risk of developing oesophageal cancer (Supplementary Table 2).  
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DISCUSSION 
 
In these two large independent population-based studies, there was little evidence of 
an association between oesophageal cancer risk and benzodiazepines, calcium 
channel blockers, nitrates or xanthines, despite the known reduction in oesophageal 
sphincter pressure associated with these medications. In contrast, β2 agonist use was 
associated with a 38% increased odds of oesophageal cancer in PCCIU but not in UK 
Biobank. 
 
The lack of association between benzodiazepines, calcium channel blockers and 
nitrates  (all known to lower oesophageal sphincter pressure) and oesophageal cancer 
is similar to the results collated in a 2012 meta-analysis which was based upon fewer 
cases (406, 875 and 980 cases, respectively).30 Our study includes over 2,300 cases 
allowing us to rule out relatively small potential increases in risk. Our study provides 
reassurance that these medications are safe with respect to oesophageal cancer risk. 
 
The previous meta-analysis observed an increase in oesophageal adenocarcinoma risk 
with theophylline (xanthine) use (OR 1.55, 95% CI 1.05, 2.28).30 Our study did not 
find a statistically significant increased risk in oesophageal cancer associated with 
xanthine use, however there was limited use of this drug in either population studied 
and when oesophageal and gastric cancer were combined in the PCCIU dataset an 
increased risk was observed for short term use (under 1 year), suggesting further 
studies containing larger numbers of xanthine users would be of value.  
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In the PCCIU data, we found β2 agonists, such as salbutamol, were associated with 
increased risk of oesophageal cancer, results which are consistent with studies by 
Vaughn et al (OR 1.70, 95% CI 0.78, 3.71), Lagergren et al (OR 1.60, 95% CI 0.81, 
3.15) and Ranka et al (OR 1.76, 95% CI 0.96, 3.23).16,17,19 Our PCCIU findings are 
also similar to a recent cohort study of progression from Barrett’s oesophagus to 
oesophageal cancer in which associations were observed with β2 agonist (adjusted 
HR 1.27, 95% CI 0.68, 2.38) and steroid inhaler use (adjusted HR 2.11, 95% CI 1.12, 
3.97), although that study contained a total of only 55 oesophageal cancer cases 
within their Barrett’s oesophagus cohort.31  
 
The cause of the increased risk of oesophageal cancer with β2 agonist use in PCCIU 
is unknown. The lack of association in UK Biobank, the lack of dose response 
association, the association between other asthma medications (e.g. steroid-based) and 
oesophageal cancer risk provide evidence against a causal interpretation, particularly 
as several studies have shown marked increases in oesophageal cancer risk in asthma 
patients.32–34 However, β2 agonists have been shown to decrease oesophageal 
sphincter pressure thus potentially increasing the risk of gastro-oesophageal reflux 
disease,35 providing a potential mechanism by which they could increase oesophageal 
cancer risk. Two previous studies have observed an increase in the premalignant 
Barrett’s oesophagus risk in users of β2 agonist36,37 suggested this association could 
reflect reverse causality, where the symptoms of gastro-oesophageal reflux mimic 
asthma leading to the use of β2 agonists.38,39 Alternatively, the increased oesophageal 
cancer risk with β2 agonist use could be real, particularly as studies have shown 
increased β2 agonist receptor expression contributes to tumour growth via the cyclic-
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AMP pathway in cancer cell lines, including the oesophageal squamous-cell 
carcinoma subtype.40,41 
 
The main strengths of the current analyses were the size (2,334 oesophageal cancer 
cases) and the use of data from two independent studies. Also, we were able to adjust 
for a wide range of confounders, particularly in UK Biobank, to rule out confounding 
by comorbidity diagnoses and lifestyle factors. Furthermore in UK Biobank we were 
able to investigate by histological subtype. Unfortunately in PCCIU this was not 
possible and consequently the inclusion of squamous cell carcinoma cases in the 
PCCIU analysis could attenuate associations, if lower oesophageal sphincter relaxing 
medications only caused adenocarcinoma. However, this potential attenuation will be 
limited as based upon our UK Biobank data over seventy percent of oesophageal 
cancer cases are likely to be adenocarcinoma. In PCCIU there was possible 
misclassification of gastric cardia cancers, however as the risk estimates for combined 
gastric and oesophageal cancer were similar to the individual cancers the impact of 
this potential confounding factor is reduced (Supplementary Table 3). Another 
significant strength is that the prescription data in PCCIU is from GP prescribing 
records and thus recall bias is eliminated.  
 
We also cannot rule out residual confounding by incompletely recorded confounders 
or unknown exposures associated with both lower oesophageal sphincter relaxing 
medication use and oesophageal cancer. We did not adjust for PPI use, Barrett’s 
oesophagus or oesophagitis because, although possible, these covariates are likely to 
be on the causal pathway between the medications and oesophageal cancer. Finally, 
dose response analyses could only be performed in the PCCIU dataset and were 
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conducted by number of prescriptions, but as the length of prescriptions may vary this 
could result in some measurement error in analysis of longer-term use. 
 
In conclusion, there was little evidence that benzodiazepines, nitrates, and calcium 
channel blockers increase oesophageal cancer risk providing reassurance that these 
widely used medications are not associated with oesophageal cancer. The increased 
risk of oesophageal cancer with β2 agonist merits further investigation but as the 
association was limited to one dataset, and there was no exposure response 
relationship, a causal interpretation seems less likely. 
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Table 1. Characteristics of Cases and Controls in the PCCIU and UK Biobank 
Databases 
 
 PCCIU  UK Biobank 
Characteristic 
EC cases 
 
Matched controls  
EC cases 
 
Non-EC cohort 
members 
 [n=1,979] [n=9,543] [n=355] [n=475,413] 
Year of diagnosis     
   1999 – 2003 665 (33.6%)    
   2004 – 2007 910 (46.0%)  1 (0.3%)  
   2008 – 2011 404 (20.4%)  102 (28.7%)  
   2012 – 2015    252 (71.0%)  
Age at index date/baseline     
   0-39 10 (0.5%) 52 (0.5%)   
   40-59 414 (20.9%) 2070 (21.7%) 111 (31.3%) 274,848 (57.9%) 
   60-79 1207 (61.0%) 5897 (61.8%) 244 (68.7%) 200,565 (42.1%) 
   80+ 348 (17.6%) 1524 (16.0%)   
   Mean (SD) 68.3 (11.1) 68.8 (11.3) 61.9 (5.8) 56.3 (8.1) 
   Male 1364 (68.9%) 6568 (68.8%) 266 (74.9%) 219,160 (46.2%) 
Alcohol consumption     
   None 314 (21.7%) 1430 (22.2%) 39 (11.0%) 38,178 (8.0%) 
   Low 1005 (69.5%) 4638 (72.1%) 155 (43.7%) 257,159 (54.2%) 
   High 127 (8.8%) 363 (5.6%) 154 (43.4%) 168,505 (35.5%) 
   Missing/did not answer 533 3112 7 11,571 
Smoking     
   Never 544 (32.2%) 3232 (43.8%) 109 (30.7%) 260,747 (54.9%) 
   Ex-smoker 578 (34.3%) 2383 (32.3%) 168 (47.3%) 162,538 (34.2%) 
   Current smoker 562 (33.4%) 1756 (23.8%) 77 (21.7%) 50,572 (10.7%) 
   Missing 295 2172 1 1,910 
Obesity     
   Underweight§   3 (0.9%) 2,441 (0.5%) 
   Normal weight§   67 (19.1%) 153,697 (32.5%) 
   Overweight§   162 (46.2%) 200,896 (42.5%) 
   Obese 276 (13.9%) 1945 (20.4%) 119 (33.9%) 115,436 (24.4%) 
   Missing\not obese 1703 (86.1%) 7598 (79.6%)   
   Missing   4 2,947 
Deprivation (fifths)     
   1 (least deprived) 242 (12.4%) 1141 (12.1%) 68 (19.2%) 95,083 (20.0%) 
   2 373 (19.1%) 1791 (19.0%) 61 (17.2%) 94,508 (19.9%) 
   3 406 (20.8%) 1970 (20.9%) 62 (17.5%) 94,852 (20.0%) 
   4 464 (23.8%) 2259 (24.0%) 72 (20.3%) 95,100 (20.0%) 
   5 (most deprived) 466 (23.9%) 2249 (23.9%) 92 (25.9%) 95,271 (20.1%) 
   Missing 28 133 0 599 
Selected comorbidities     
   Peptic ulcer disease 289 (14.6%) 880 (9.2%) 11 (3.1%) 5,000 (1.1%) 
   COPD 234 (11.8%) 787 (8.2%) 10 (2.8%) 7,529 (1.6%) 
   Diabetes mellitus 197 (10.0%) 922 (9.7%) 36 (10.1%) 23,868 (5.0%) 
   Acute myocardial infarction 169 (8.5%) 744 (7.8%) 18 (5.1%) 10,812 (2.3%) 
   Cerebrovascular disease 166 (8.4%) 750 (7.9%) 11 (3.1%) 6,327 (1.3%) 
COPD = Chronic obstructive pulmonary disease  
EC = Oesophageal cancer 
§Data not available in PCCIU dataset 
Comorbidity diagnosed from before the start of follow up to one year prior to end of follow up 
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Table 2. Association Between Medications That Relax the Lower Oesophageal 
Sphincter and Risk of Oesophageal Cancer in PCCIU Case-Control Data. 
 
Medication Cases Controls 
Unadjusted OR 
(95% CI) 
Adjusted ORa 
(95% CI) 
P-value 
 n=1,979 n=9,543 n=11,522 n=11,522  
Any LOS medication      
     Never user 1,084 (54.8%) 5,816 (60.9%) Ref Ref . 
     Ever user 895 (45.2%) 3,727 (39.1%) 1.31 (1.18,1.45) 1.23 (1.10,1.38) <0.01 
     1-12 prescriptions 394 (19.9%) 1,591 (16.7%) 1.35 (1.18,1.53) 1.30 (1.13,1.48) <0.01 
     >12 prescriptions 501 (25.3%) 2,136 (22.4%) 1.27 (1.13,1.44) 1.17 (1.02,1.35) 0.03 
Benzodiazepines      
     Never user 1,782 (90.0%) 8,577 (89.9%) Ref Ref . 
     Ever user 197 (10.0%) 966 (10.1%) 0.98 (0.83,1.15) 0.94 (0.79,1.11) 0.46 
     1-12 141 (7.1%) 643 (6.7%) 1.07 (0.88,1.29) 1.03 (0.85,1.26) 0.75 
     >12 56 (2.8%) 323 (3.4%) 0.80 (0.60,1.08) 0.76 (0.56,1.02) 0.07 
Calcium channel blockers 
     
     Never user 1,556 (78.6%) 7,655 (80.2%) Ref Ref . 
     Ever user 423 (21.4%) 1,888 (19.8%) 1.10 (0.97,1.25) 1.05 (0.92,1.20) 0.47 
     1-12 150 (7.6%) 712 (7.5%) 1.04 (0.86,1.25) 0.99 (0.81,1.20) 0.90 
     >12 273 (13.8%) 1,176 (12.3%) 1.15 (0.99,1.33) 1.09 (0.93,1.28) 0.28 
Nitrates 
     
     Never user 1,683 (85.0%) 8,298 (87.0%) Ref Ref . 
     Ever user 296 (15.0%) 1,245 (13.0%) 1.17 (1.02,1.35) 1.09 (0.92,1.29) 0.31 
     1-12 182 (9.2%) 713 (7.5%) 1.25 (1.05,1.49) 1.19 (0.98,1.44) 0.08 
     >12 114 (5.8%) 532 (5.6%) 1.05 (0.85,1.30) 0.94 (0.74,1.20) 0.62 
β2 agonists 
     
     Never user 1,655 (83.6%) 8,387 (87.9%) Ref Ref . 
     Ever userb 324 (16.4%) 1,156 (12.1%) 1.43 (1.25,1.64) 1.38 (1.12,1.70) <0.01 
     1-12b 176 (8.9%) 603 (6.3%) 1.50 (1.25,1.79) 1.42 (1.14,1.77) <0.01 
     >12b 148 (7.5%) 553 (5.8%) 1.36 (1.12,1.64) 1.26 (0.94,1.69) 0.12 
Xanthines 
    
     Never user 1,951 (98.6%) 9,464 (99.2%) Ref Ref . 
     Ever userb 28 (1.4%) 79 (0.8%) 1.76 (1.13,2.73) 1.40 (0.88,2.22) 0.16 
     1-12b 16 (0.8%) 40 (0.4%) 2.01 (1.12,3.62) 1.64 (0.90,3.00) 0.11 
     >12b 12 (0.6%) 39 (0.4%) 1.50 (0.78,2.88) 1.16 (0.59,2.28) 0.66 
 
LOS = lower oesophageal sphincter 
a Calculated using conditional logistic regression, with age, gender, location of residence (deprivation 
level) and year of diagnosis were accounted for by matched design, and adjustment for acute 
myocardial infarction, congestive cardiac failure, peripheral vascular disease, cerebrovascular disease, 
dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, 
diabetes mellitus, rheumatoid arthritis,  chronic kidney disease, liver disease, statins, and aspirin  
bAdditional adjustment for steroid-based inhalers 
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Table 3. Sensitivity Analysis for the Association Between Medications That Relax the Lower Oesophageal Sphincter and Risk of Oesophageal 
Cancer in the PCCIU 
 
Medication Cases Controls 
Unadjusted OR 
(95% CI) 
Adjusted ORa 
(95% CI) 
P-value 
Any LOS medication      
     Exposure lag (excl 2 years)b 781 (39.5%) 3,287 (34.4%) 1.25 (1.13,1.39) 1.17 (1.04,1.32) <0.01 
     Ever use ≥3c 718 (36.3%) 3,057 (32.0%) 1.21 (1.09,1.35) 1.11 (0.99,1.25) 0.08 
     Lifestyle adjustedd 710 (50.0%) 2,738 (44.4%) 1.30 (1.14,1.47) 1.22 (1.06,1.41) <0.01 
     Lifestyle adjusted (MI)d 895 (45.2%) 3,727 (39.1%) 1.31 (1.18,1.45) 1.24 (1.10,1.39) <0.01 
Benzodiazepines      
     Exposure lag (excl 2 years)b 162 (8.2%) 797 (8.4%) 0.97 (0.81,1.16) 0.94 (0.79,1.13) 0.53 
     Ever use ≥3c 98 (5.0%) 516 (5.4%) 0.89 (0.71,1.12) 0.85 (0.67,1.06) 0.15 
     Lifestyle adjustedd 156 (11.0%) 697 (11.3%) 1.00 (0.82,1.22) 0.87 (0.71,1.07) 0.18 
     Lifestyle adjusted (MI)d 197 (10.0%) 966 (10.1%) 0.98 (0.83,1.15) 0.87 (0.73,1.03) 0.10 
Calcium channel blockers      
     Exposure lag (excl 2 years)b 366 (18.5%) 1,627 (17.0%) 1.11 (0.97,1.26) 1.05 (0.91,1.21) 0.49 
     Ever use ≥3c 387 (19.6%) 1,684 (17.6%) 1.14 (1.00,1.30) 1.09 (0.95,1.25) 0.20 
     Lifestyle adjustedd 348 (24.5%) 1,451 (23.5%) 1.09 (0.94,1.26) 1.08 (0.92,1.27) 0.33 
     Lifestyle adjusted (MI)d 423 (21.4%) 1,888 (19.8%) 1.10 (0.97,1.25) 1.10 (0.96,1.26) 0.16 
Nitrates      
     Exposure lag (excl 2 years)b 247 (12.5%) 1,095 (11.5%) 1.10 (0.94,1.28) 1.00 (0.84,1.19) 0.99 
     Ever use ≥3c 212 (10.7%) 942 (9.9%) 1.08 (0.92,1.27) 0.96 (0.79,1.16) 0.65 
     Lifestyle adjustedd 243 (17.1%) 936 (15.2%) 1.15 (0.97,1.37) 1.09 (0.88,1.34) 0.42 
     Lifestyle adjusted (MI)d 296 (15.0%) 1,245 (13.0%) 1.17 (1.02,1.35) 1.11 (0.94,1.32) 0.23 
β2 agonists      
     Exposure lag (excl 2 years)b,e 280 (14.1%) 999 (10.5%) 1.41 (1.22,1.63) 1.33 (1.07,1.66) 0.01 
     Ever use ≥3c,e 247 (12.5%) 893 (9.4%) 1.38 (1.19,1.60) 1.23 (0.97,1.57) 0.09 
     Lifestyle adjustedd,e 257 (18.1%) 836 (13.6%) 1.39 (1.18,1.64) 1.25 (0.97,1.61) 0.09 
     Lifestyle adjusted (MI)d,e 324 (16.4%) 1,156 (12.1%) 1.43 (1.25,1.64) 1.38 (1.12,1.70) <0.01 
Not Adjusting for steroid-based 
inhalers 
324 (16.4%) 1,156 (12.1%) 1.43 (1.25,1.64) 1.27 (1.08,1.48) <0.01 
Xanthines      
     Exposure lag (excl 2 years)b,e 23 (1.2%) 68 (0.7%) 1.67 (1.03,2.70) 1.32 (0.80,2.18) 0.28 
     Ever use ≥3c,e 18 (0.9%) 54 (0.6%) 1.63 (0.95,2.80) 1.26 (0.71,2.21) 0.43 
     Lifestyle adjustedd,e 23 (1.6%) 55 (0.9%) 1.72 (1.01,2.93) 1.36 (0.77,2.41) 0.29 
Lifestyle adjusted (MI)d,e 28 (1.4%) 79 (0.8%) 1.76 (1.13,2.73) 1.40 (0.88,2.22) 0.16 
Not Adjusting for steroid-  28 (1.4%) 79 (0.8%) 1.76 (1.13,2.73) 1.44 (0.91,2.28) 0.12 
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based inhalers 
 
*per 1000 person years 
LOS = lower oesophageal sphincter 
a
Calculated using conditional logistic regression, with age, gender, location of residence (deprivation level) and year of diagnosis were accounted for by matched design, and 
adjustment for acute myocardial infarction, congestive cardiac failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, 
connective tissue disease, peptic ulcer disease, diabetes mellitus,, rheumatoid arthritis, chronic kidney disease, liver disease, statins and aspirin 
b
Analysis excludes patients who died within 2 years of oesophageal cancer diagnosis 
c
Analysis restricted for those patients who received a minimum of 3 prescriptions of these medications 
d
Additional adjustment for lifestyle factors: obesity, alcohol intake and positive smoking history  
eAdditional adjustment for steroid-based inhalers 
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Table 4. Association Between Medications That Relax the Lower Oesophageal 
Sphincter and Risk of Oesophageal Cancer in UK Biobank Cohort by Subtype. 
 
 
*per 1000 person years 
LOS = lower oesophageal sphincter 
a
Cox regression model adjusted for acute myocardial infarction, congestive cardiac failure, peripheral 
vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective 
tissue disease, peptic ulcer disease, diabetes mellitus, rheumatoid arthritis, chronic kidney disease, 
hypertension, Alzheimer’s disease, liver disease, peptic ulcer disease, sex, body mass index, fruit and 
vegetable intake, alcohol intake, smoking status, deprivation level, educational degree, statins, aspirin 
and age accounted for by using age as the underlying time scale in the Cox regression model 
bAdditionally adjusted for steroid-based inhalers 
 Users  Non-users  
Unadjusted HR 
(95% CI) 
Adjusted HRa  (95% 
CI) 
 
Medication 
Cases  
(person-years*) 
Cases  
(person-years*) 
p 
      
Any oesophageal cancer   n=355 n=323  
  Any LOS relaxing medication 82 (299.5) 273 (1859.1) 1.48 (1.15,1.89) 1.29 (0.97,1.71) 0.08 
  Benzodiazepines 4 (12.4) 351 (2142.5) 1.68 (0.63,4.50) 1.47 (0.54,3.96) 0.44 
  Calcium channel blockers 39 (143.0) 316 (2011.9) 1.21 (0.86,1.69) 0.94 (0.64,1.36) 0.92 
  Nitrates 8 (26.7) 347 (2128.2) 1.22 (0.61,2.47) 0.85 (0.40,1.82) 0.69 
  β2 agonistsb 41 (148.6) 314 (2006.3) 1.67 (1.21,2.31) 1.21 (0.70,2.08) 0.49 
  Xanthinesb 2 (2.6) 324 (2152.3) 3.74 (0.93,15.00) 2.46 (0.58,10.32) 0.22 
      
Oesophageal adenocarcinoma   n=258 n=232  
  Any LOS relaxing medication 58 (299.5) 200 (1859.1) 1.41 (1.05,1.90) 1.18 (0.84,1.65) 0.33 
  Benzodiazepines 3 (12.4) 255 (2142.5) 1.73 (0.55,5.39) 1.70 (0.54,5.37) 0.36 
  Calcium channel blockers 27 (143.0) 231 (2011.9) 1.13 (0.76,1.69) 0.86 (0.52,1.26) 0.50 
  Nitrates 7 (26.7) 251 (2128.2) 1.47 (0.69,3.11) 1.05 (0.46,2.40) 0.90 
  β2 agonistsb 29 (148.6) 229 (2006.3) 1.62 (1.10,2.38) 1.27 (0.67,2.41) 0.47 
  Xanthinesb 2 (2.6) 256 (2152.3) 5.12 (1.27,20.59) 3.78 (0.88,16.23) 0.07 
      
Squamous cell carcinoma   n=75 n=70  
  Any LOS relaxing medication 18 (299.5) 57 (1859.1) 1.59 (0.93,2.71) 1.66 (0.91,3.03) 0.10 
  Benzodiazepines 1 (12.4) 74 (2142.5) 2.01 (0.28,14.49) 1.26 (0.17,9.23) 0.82 
  Calcium channel blockers 7 (143.0) 68 (2011.9) 1.03 (0.47,2.27) 1.06 (0.44,2.54) 0.90 
  Nitrates 0 75 (2128.2) - - - 
  β2 agonistsb 12 (148.6) 63 (2006.3) 2.45 (1.32,4.54) 1.79 (0.65,4.97) 0.26 
  Xanthinesb 0 75 (2152.3) - - - 
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Table 5. Sensitivity Analysis for the Association Between Medications That Relax the 
Lower Oesophageal Sphincter and Risk of Oesophageal Cancer in the UK Biobank 
 
Medication 
Users [cases] 
(person years*) 
Non-users [cases] 
(person years*) 
Unadjusted HR 
(95% CI) 
Adjusted HRa (95% 
CI) 
p  
Any LOS medication      
     Exposure lag (excl 2 years)b 66 (233.5) 222 (1455.9) 1.48 (1.12,1.96) 1.10 (0.77,1.56) 0.61 
Benzodiazepines      
      Exposure lag (excl 2 years)b 1 (9.7) 287 (1676.2) 0.51 (0.07,3.66) 0.43 (0.06,3.11) 0.41 
Calcium channel blockers      
      Exposure lag (excl 2 years)b 32 (111.0) 256 (1574.8) 1.25 (0.86,1.81) 1.03 (0.68,1.55) 0.91 
Nitrates      
      Exposure lag (excl 2 years)b 7 (20.9) 281 (1665.0) 1.34 (0.63,2.84) 0.89 (0.39,2.01) 0.78 
β2 agonists      
     Exposure lag (excl 2 years)b,c 32 (116.2) 256 (1569.7) 1.60 (1.11,2.32) 1.12 (0.61,2.08) 0.71 
     In asthma patientse,c 35 (129.5) 13 (121.6) 2.34 (1.24,4.44) 1.69 (0.76,3.78) 0.20 
     In non-asthma patientsf,i 6 (19.1) 301 (1884.7) 1.45 (0.64,3.25) 0.57 (0.17,1.92) 0.37 
  Additionally adjusted for asthmag,i 41 (148.6) 314 (2006.3) 1.67 (1.21,2.31) 1.24 (0.66,2.34) 0.51 
  Without adjusting for steroid-
based inhalersd 
41 (148.6) 314 (2006.3) 1.67 (1.21,2.31) 1.66 (1.16,2.37) 0.01 
Xanthines      
     Exposure lag (excl 2 years)b,c 2 (2.0) 286 (1683.9) 4.70 (1.17,18.90) 3.16 (0.74,13.44) 0.12 
     In asthma patientse,c 2 (2.2) 46 (249.0) 4.05 (0.98,16.72) 3.55 (0.83,15.25) 0.09 
Without adjusting for steroid-
based inhalersd 
2 (2.6) 324 (2152.3) 3.74 (0.93,15.00) 3.58 (0.87,14.82) 0.08 
Steroid-based inhalers      
     Overall riskh 31 (92.8) 324 (2042.1) 1.86 (1.29,2.69) 1.94 (1.32,2.86) <0.01 
Adjusting for β2 agonistsh 31 (92.8) 324 (2042.1) 1.86 (1.29,2.69) 1.65 (0.91,2.99) 0.10 
 
*per 1000 person years 
LOS = lower oesophageal sphincter 
a
Cox regression model adjusted for acute myocardial infarction, congestive cardiac failure, peripheral 
vascular disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective 
tissue disease, peptic ulcer disease, diabetes mellitus, rheumatoid arthritis, chronic kidney disease, 
hypertension, Alzheimer’s disease, liver disease, peptic ulcer disease, sex, body mass index, fruit and 
vegetable intake, alcohol intake, smoking status, deprivation level, educational degree, statins, aspirin 
and age accounted for by using age as the underlying time scale in the Cox regression model 
b
Analysis excluding patients who died within 2 years of oesophageal cancer diagnosis 
cAdditional adjustment for steroid-based inhalers 
d
Main analysis (excluding 1 year after diagnosis) without adjustment for steroid-based inhalers
  
e
Main analysis (excluding 1 year after diagnosis) stratified by restricting to patients with a self reported 
asthma diagnosis  
fMain analysis (excluding 1 year after diagnosis) stratified by restricting to patients without an asthma 
diagnosis  
g
Main analysis (excluding 1 year after diagnosis) with additional adjustment for asthma diagnosis 
h
Main analysis (excluding 1 year after diagnosis) for patients prescribed steroid-based inhalers 
iAdditional adjustment for β2 agonist prescriptions 
 
 
Page 30 of 34International Journal of Cancer
Supplementary Table 1. Generic and propriety names for medications included in this 
study 
 
 
Type of medication Generic / propriety medication name 
Aspirin Asasantin, Aspirin, Caprin, Co-codaprin, Micropirin, Migramax, Nu-Seals 
Benzodiazepine Alprazolam, Ativan, Chlordiazepoxide, Dalmane, Dialar, Diazemuls, Diazepam, 
Diazepam Desitin, Diazepam Rectubes, Flurazepam, Librium, Loprazolam, 
Lorazepam, Mogadon, Nitrazepam, Oxazepam, Rimapam, Stesolid, Temazepam, 
Tensium, Xanax 
Calcium channel blocker Adalat, Adipine, Adizem, Amlodipine, Angitil, Beta-Adalat, Cardene, 
Cardioplen, Coracten, Cordilox, Dilcardia, Diltiazem, Dilzem, Exforge, 
Felodipine, Felogen, Felotens, Fortipine, Isradipine, Istin, Keloc, Lacidipine, 
Lercandipine, Motens, Neofel, Nicardipine, Nifedipine, Nifedipress, Nimodipine, 
Nimotop, Parmid, Plendil, Securon, Slozem, Tenif, Tensipine, Tildiem, Triapin, 
Univer, Valni, Vascalpha, Verapamil, Verapress, Vertab, Viazem, Zanidip, 
Zemtard, Zolvera 
Nitrate Angitak, Chemydur, Clytrin, Coro-nitro, Deponit, Elantan, GTN, Glyceryl 
trinitrate, Imdur, Isib, Ismo, Isodur, Isoket, Isosorbide dinitrate, Isosorbide 
mononitrate, Isotard, Minitran, Modisal, Monomax, Monomil, Monosorb, Nitro-
Dur, Nitrocine, Nitrolingual, Nitromin, Nitronal, Percutol, Transderm-Nitro, 
Zemon 
β2 agonist Airomir, Airsalb, Asmasal, Atimos, Bambec, Bambuterol, Bricanyl, Combivent, 
Duaklir, Easyhaler, Flutiform, Foradil, Formoterol, Fostair, Indacaterol, Ipramol, 
Neovent, Olodaterol, Onbrez Breezhaler, Oxis, Pulvinal, Salamol, Salapin, 
Salbulin, Salbutamol, Salipraneb, Salmeterol, Seretide, Serevent, Spiolto, 
Striverdi, Symbicort, Terbutaline, Ultibro Breezhaler, Ventmax, Ventolin 
Statin Atorvastatin, Cholib, Crestor, Dorisin, Fluvastatin, Inegy, Lescol, Lipitor, 
Lipostat, Luvinsta, Pinmactil, Pravastatin, Rosuvastatin, Simvador, Simvastatin, 
Stefluvin, Zocor 
Xanthine Aminophylline, Nuelin, Phyllocontin, Slo-phyllin, Theophylline, Uniphyllin 
Steroid inhalers Asmabec, Asmanex, Bambec, Beclometasone, Beclomethasone, Budenofalk, 
Budesonide, Flixotide, Fluticasone, Pulmicort, Qvar, Seretide, Symbicort 
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Supplementary Table 2. Commonly prescribed medications within each substance 
(greater than 1% of total prescriptions) [PCCIU and UK Biobank databases] 
 
 
PCCIU 
 
Cases Controls 
Unadjusted OR 
(95% CI) 
Adjusted ORo 
(95% CI) 
p 
Benzodiazepine      
Diazepama 95 (4.8%) 549 (5.8%) 0.82 (0.66,1.03) 0.80 (0.64,1.01) 0.06 
Temazepamb 62 (3.1%) 318 (3.3%) 0.93 (0.70,1.23) 0.91 (0.68,1.20) 0.50 
Nitrazepamc 19 (1.0%) 117 (1.2%) 0.78 (0.48,1.28) 0.75 (0.46,1.24) 0.27 
Calcium channel blockers      
Amlodipined 215 (10.9%) 1,022 (10.7%) 1.01 (0.86,1.18) 0.96 (0.81,1.13) 0.63 
Nifedipinee 101 (5.1%) 475 (5.0%) 1.02 (0.82,1.28) 1.00 (0.80,1.26) 0.97 
Diltiazemf 82 (4.1%) 354 (3.7%) 1.13 (0.88,1.44) 1.01 (0.78,1.30) 0.96 
Felodipineg 34 (1.7%) 153 (1.6%) 1.08 (0.73,1.59) 1.08 (0.73,1.60) 0.69 
Verapamilh 17 (0.9%) 92 (1.0%) 0.89 (0.53,1.50) 0.81 (0.48,1.38) 0.44 
Nitrates      
Glyceryl Trinitratei 273 (13.8%) 1,095 (11.5%) 1.23 (1.07,1.43) 1.17 (0.98,1.39) 0.08 
Isosorbide Mononitratej 144 (7.3%) 607 (6.4%) 1.14 (0.94,1.38) 1.03 (0.84,1.28) 0.76 
β2 agonistsq    
Salbutamolk 279 (14.1%) 1,007 (10.6%) 1.40 (1.21,1.62) 1.26 (1.03,1.54) 0.03 
Salmeteroll 98 (5.0%) 335 (3.5%) 1.45 (1.15,1.83) 1.18 (0.88,1.59) 0.27 
Terbutalinem 58 (2.9%) 192 (2.0%) 1.46 (1.08,1.98) 1.25 (0.90,1.75) 0.18 
Formoteroln 26 (1.3%) 84 (0.9%) 1.50 (0.95,2.36) 1.15 (0.70,1.89) 0.57 
 
 
 
 
UK Biobank 
 
 
Users [cases] 
(person years) 
Non-users [cases] 
(person years) 
Unadjusted HR 
(95% CI) 
Adjusted ORp 
(95% CI) 
p 
Benzodiazepine      
Diazepama 3 (5716) 352 (2149181) 3.13 (1.01,9.76) 2.59 (0.83,8.13) 0.10 
Calcium channel blockers      
Amlodipined 23 (87968) 332 (2066929) 1.17 (0.76,1.78) 0.91 (0.57,1.43) 0.67 
Nifedipinee 6 (12233) 349 (2142664) 2.13 (0.95,4.78) 1.96 (0.87,4.46) 0.11 
Diltiazemf 3 (12898) 352 (2141999) 0.95 (0.31,2.97) 0.80 (0.25,2.52) 0.70 
Felodipineg 4 (19447) 351 (2135450) 0.88 (0.33,2.36) 0.79 (0.29,2.14) 0.64 
Verapamilh 2 (4475) 353 (2150422) 1.89 (0.47,7.61) 1.87 (0.46,7.53) 0.38 
Nitrates       
Glyceryl Trinitratei 7 (20632) 348 (2134265) 1.40 (0.66,2.96) 1.00 (0.45,2.23) 0.99 
Isosorbide Mononitratej 5 (11957) 350 (2142939) 1.68 (0.69,4.06) 1.18 (0.47,2.98) 0.72 
β2 agonistsq     
Salbutamolk 31 (111919) 324 (2042978) 1.71 (1.18,2.47) 1.34 (0.84,2.15) 0.22 
Salmeteroll 17 (39994) 338 (2114903) 2.29 (1.41,3.73) 1.59 (0.82,3.06) 0.17 
Formoteroln 2 (15002) 353 (2139895) 0.72 (0.18,2.88) 0.42 (0.10,1.76) 0.23 
 
a
Diazepam: Dialar, Diazemuls, Diazepam, Diazepam Desitin, Diazepam Rectubes, Stesolid, Tensium; 
b
Temazepam: Temazepam; 
c
Nitrazepam: Mogadon, Nitrazepam; 
d
Amlodipine: Amlodipine, Exforge, 
Istin; eNifedipine: Adalat, Beta-adalat, Coracten, Fortipine, Nifedipine, Nifedipress, Tenif, Valni; 
f
Diltiazem: Adizem, Angitil, Dilcardia, Diltiazem, Dilzem, Slozem, Tildiem, Viazem, Zemtard; 
g
Felodipine: Cardioplen, Felodipine, Felogen, Felotens, Keloc, Neofel, Parmid, Plendil, Triapin, 
Vascalpha; 
h
Verapamil: Cordilox, Securon, Univer, Verapamil, Verapress, Vertab, Zolvera; 
i
Glyceryl 
Trinitrate: Coro-nitro, Deponit, GTN, Glyceryl trinitrate, Glytrin, Minitran, Nitrocine, Nitrolingual, 
Nitromin, Nitronal, Percutol; 
j
Isosorbide Mononitrate: Chemydur, Elantan, Imdur, Isib, Ismo, Isodur, 
Isosorbide mononitrate, Isotard, Modisal, Monomax, Monomil, Monosorb, Zemon; 
k
Salbutamol: 
Airomir, Airsalb, Asmasal, Combivent ,Salamol, Salapin, Salbulin, Salbutamol, Salipraneb, Ventmax, 
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Ventolin; 
l
Salmeterol: Neovent, Salmeterol, Seretide, Serevent; 
m
Terbutaline: Bricanyl, Terbutaline; 
n
Formoterol: Atimos, Duaklir, Flutiform, Foradil, Formoterol, Fostair, Oxis, Symbicort 
 
oCalculated using conditional logistic regression, with age, gender, location of residence (deprivation 
level) and year of diagnosis were accounted for by matched design, and adjustment for acute 
myocardial infarction, congestive cardiac failure, peripheral vascular disease, cerebrovascular disease, 
dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, 
diabetes mellitus, chronic kidney disease, leukaemia, malignant lymphoma, liver disease, statins and 
aspirin
 
 
p
Cox regression model additionally contains hypertension, diabetes, chronic obstructive pulmonary 
disease, congestive cardiac failure, acute myocardial infarction, Alzheimer’s disease, renal failure, liver 
disease, peptic ulcer disease, peripheral vascular disease, sex, body mass index, fruit and vegetable 
intake, alcohol intake, smoking status, deprivation level, educational degree, statins, aspirin and age 
accounted for by using age as the underlying time scale in the Cox regression model 
 
qAdditional adjustment for steroid-based inhalers 
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Supplementary Table 3. Odds ratios (95% confidence interval) for risk of developing 
either gastric or oesophageal cancer for patients prescribed LOS relaxing medication 
(PCCIU database) 
 
Medication Cases Controls 
Unadjusted OR 
(95% CI) 
Adjusted ORa 
(95% CI) 
P-Value 
 n n    
Any LOS medication      
     Never user 1,671 (53.9%) 8,867 (59.4%) Ref Ref . 
     Ever user 1,427 (46.1%) 6,070 (40.6%) 1.26 (1.16,1.37) 1.18 (1.08,1.30) <0.01 
     1-12 prescriptions 610 (19.7%) 2,547 (17.1%) 1.28 (1.16,1.43) 1.23 (1.10,1.37) <0.01 
     >12 prescriptions 817 (26.4%) 3,523 (23.6%) 1.24 (1.12,1.36) 1.14 (1.02,1.27) 0.02 
Benzodiazepines      
     Never user 2,772 (89.5%) 13,340 (89.3%) Ref Ref . 
     Ever user 326 (10.5%) 1,597 (10.7%) 0.97 (0.85,1.11) 0.93 (0.81,1.06) 0.25 
     1-12 prescriptions 227 (7.3%) 1,049 (7.0%) 1.05 (0.90,1.22) 1.01 (0.87,1.18) 0.89 
     >12 prescriptions 99 (3.2%) 548 (3.7%) 0.83 (0.67,1.04) 0.78 (0.62,0.97) 0.03 
Calcium channel blockers     
     Never user 2,388 (77.1%) 11,860 (79.4%) Ref Ref . 
     Ever user 710 (22.9%) 3,077 (20.6%) 1.14 (1.04,1.26) 1.10 (0.99,1.22) 0.08 
     1-12 prescriptions 256 (8.3%) 1,178 (7.9%) 1.08 (0.93,1.25) 1.04 (0.90,1.21) 0.57 
     >12 prescriptions 454 (14.7%) 1,899 (12.7%) 1.19 (1.06,1.33) 1.14 (1.00,1.29) 0.04 
Nitrates      
     Never user 2,591 (83.6%) 12,900 (86.4%) Ref Ref . 
     Ever user 507 (16.4%) 2,037 (13.6%) 1.24 (1.11,1.38) 1.18 (1.04,1.35) 0.01 
     1-12 prescriptions 311 (10.0%) 1,162 (7.8%) 1.33 (1.17,1.52) 1.29 (1.11,1.50) <0.01 
     >12 prescriptions 196 (6.3%) 875 (5.9%) 1.10 (0.93,1.30) 1.02 (0.84,1.23) 0.86 
β2 agonists     
     Never user 
2,590 
(83.6%) 13,003 (87.1%) Ref Ref . 
     Ever userb 508 (16.4%) 1,934 (12.9%) 1.32 (1.19,1.48) 1.24 (1.05,1.46) 0.01 
     1-12 prescriptionsb 272 (8.8%) 1,004 (6.7%) 1.37 (1.19,1.58) 1.27 (1.07,1.51) <0.01 
     >12 prescriptionsb 236 (7.6%) 930 (6.2%) 1.27 (1.10,1.48) 1.13 (0.90,1.43) 0.29 
Xanthines      
     Never user 
3,053 
(98.5%) 14,797 (99.1%) Ref Ref . 
     Ever userb 45 (1.5%) 140 (0.9%) 1.55 (1.10,2.18) 1.31 (0.91,1.88) 0.14 
     1-12 prescriptionsb 27 (0.9%) 63 (0.4%) 2.13 (1.35,3.36) 1.75 (1.09,2.80) 0.02 
     >12 prescriptionsb 18 (0.6%) 77 (0.5%) 1.09 (0.65,1.83) 0.95 (0.55,1.62) 0.85 
 
aCalculated using conditional logistic regression, with age, gender, location of residence (deprivation 
level) and year of diagnosis were accounted for by matched design, and adjustment for acute 
myocardial infarction, congestive cardiac failure, peripheral vascular disease, cerebrovascular disease, 
dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, 
diabetes mellitus, rheumatoid arthritis, chronic kidney disease, liver disease, statins and aspirin. 
bAdditional adjustment for steroid-based inhalers 
 
LOS = lower oesophageal sphincter 
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